Migraine Treatment Global Market Report 2024

The global migraine treatment market has grown strongly in recent years. It will grow from $2.94 billion in 2023 to $3.22 billion in 2024 at a compound annual growth rate (CAGR) of 9.6%. The growth observed in the historical period can be attributed to several factors, including the rising prevalence of migraines, increased spending on healthcare, advancements in existing drug formulations, expansion of clinical research, and the innovation of new therapeutic approaches.

The global migraine treatment market is expected to see rapid growth in the next few years. It will grow to $4.78 billion in 2028 at a compound annual growth rate (CAGR) of 10.4%. The projected growth is expected to stem from heightened awareness and educational efforts, the advent of monoclonal antibodies, a heightened emphasis on pediatric migraine treatments, the broadening scope of non-pharmacological interventions, and global initiatives supporting migraine research. Significant trends in this period encompass advancements in treatment methodologies, the rise of wearable devices and digital therapeutics, the integration of telemedicine for remote consultations, patient-focused care models, the expansion of the generic drug market, and the development of oral CGRP inhibitors.

The burgeoning prevalence of migraines is anticipated to drive substantial growth within the migraine treatment market. Characterized by one-sided, severe headaches or pulsating sensations, migraines necessitate effective treatment to curb future attacks and manage associated symptoms. According to the Centers for Disease Control and Prevention (CDC) in June 2023, 4.3% of individuals aged 18 and above reported experiencing migraines or headaches at least once every three months in 2021. This escalating prevalence underpins the growth trajectory of the migraine treatment market.

The escalating number of clinical trials stands as a catalyst for the migraine treatment market's expansion. These trials, involving human participants, aim to evaluate the safety and effectiveness of new medical interventions for migraines. They offer insights into personalized treatment strategies and potentially more efficient therapies. As per Xtalks in May 2023, there were 452,604 registered clinical studies on ClinicalTrials.gov, with 64,838 actively seeking participants - a significant increase from 2021's 365,000 registered trials. This surge in clinical trials actively contributes to the burgeoning migraine treatment market.

Technological advancements form a pivotal trend driving the growth of the migraine treatment market. Key market players are leveraging innovative technologies to solidify their market presence. For example, in March 2021, Neurolief, an Israel-based company specializing in proprietary digital therapeutics neuromodulation technology, introduced 'Brain Neuromodulation Technology.' This non-invasive system serves as a breakthrough for at-home acute migraine treatment.

Major players in the migraine treatment market prioritize product approvals, such as the zavzpret (zavegepant) migraine nasal spray, to bolster market revenues. Zavzpret, a calcitonin gene-related peptide (CGRP) receptor antagonist nasal spray, targets the acute management of adult migraines. Notably, Pfizer Inc. received FDA approval for zavzpret (zavegepant) in March 2023. This nasal spray offers immediate relief for adult migraine attacks, aiming to provide pain relief with a single spray. The FDA's endorsement marks a significant milestone for migraine sufferers seeking alternatives to oral medications for prompt pain relief.

In May 2022, Pfizer Inc., a prominent biopharmaceutical company based in the US, successfully completed the acquisition of Biohaven Pharmaceutical Holding Company Ltd. for an estimated $11.6 billion. This strategic acquisition positions Pfizer to further its commitment in providing effective treatments for individuals worldwide afflicted by migraines. Biohaven Pharmaceutical Holding Company Ltd., also based in the US, possesses a diverse product portfolio focused on addressing neuropsychiatric diseases and neurological disorders.

Major companies operating in the migraine treatment market report are Pfizer Inc., Eli Lilly and Company, Amgen Inc., GlaxoSmithKline PLC, Novartis AG, Bayer AG, Allergan PLC, Abbott Laboratories, Allodynic Therapeutics LLC, AOBiome LLC, AstraZeneca PLC, Bausch Health Companies Inc., Boehringer Ingelheim International GmbH, Catalent Inc., Dr. Reddy's Laboratories Limited, Impel Pharmaceuticals Inc., AbbVie Inc., Alder BioPharmaceuticals Inc., Astellas Pharma Inc., Biohaven Pharmaceutical Holding Company Ltd., Bristol-Myers Squibb Company, CoLucid Pharmaceuticals Inc., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Endo International PLC, Impax Laboratories Inc., Johnson & Johnson Inc., Lannett Company Inc., Lupin Limited, Merck & Co. Inc., Mylan N.V., Novo Nordisk A/S

North America was the largest region in the migraine treatment market in 2023. The regions covered in the migraine treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the migraine treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Different types of migraine treatments cater to varying migraine presentations. Episodic migraine treatment addresses instances where individuals experience headaches for 0-14 days per month. This form of treatment encompasses various acute options tailored specifically for episodic migraines. Available treatments include acute/abortive methods, preventive/prophylactic approaches, as well as non-pharmacological therapies and devices. These treatments find applications across diverse settings, including hospitals, clinics, homecare, and other end-user environments.

This report provides migraine treatment market statistics, including migraine treatment industry global market size, regional shares, competitors with a migraine treatment market share, detailed migraine treatment market segments, market trends and opportunities, and any further data you may need to thrive in the migraine treatment industry. This migraine treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The migraine treatment market includes revenues earned by entities by providing branded and generic migraine treatment services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.